These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18564222)

  • 1. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
    Isotani M; Ishida N; Tominaga M; Tamura K; Yagihara H; Ochi S; Kato R; Kobayashi T; Fujita M; Fujino Y; Setoguchi A; Ono K; Washizu T; Bonkobara M
    J Vet Intern Med; 2008; 22(4):985-8. PubMed ID: 18564222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.
    Yamada O; Kobayashi M; Sugisaki O; Ishii N; Ito K; Kuroki S; Sasaki Y; Isotani M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2011 Jul; 142(1-2):101-6. PubMed ID: 21561667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
    Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice.
    Kobie K; Kawabata M; Hioki K; Tanaka A; Matsuda H; Mori T; Maruo K
    Res Vet Sci; 2007 Apr; 82(2):239-41. PubMed ID: 16919303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.
    Rossi G; Bertani C; Mari S; Marini C; Renzoni G; Ogilvie G; Magi GE
    Vet Res Commun; 2013 Jun; 37(2):101-8. PubMed ID: 23315207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation.
    Irie M; Takeuchi Y; Ohtake Y; Suzuki H; Nagata N; Miyoshi T; Kagawa Y; Yamagami T
    J Vet Med Sci; 2015 Nov; 77(11):1535-9. PubMed ID: 26074249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy.
    Kobayashi M; Sugisaki O; Ishii N; Yamada O; Ito K; Kuroki S; Sasaki Y; Ono K; Washizu T; Bonkobara M
    Vet J; 2012 Jul; 193(1):264-7. PubMed ID: 22153896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation.
    Kobayashi M; Kuroki S; Ito K; Yasuda A; Sawada H; Ono K; Washizu T; Bonkobara M
    Vet J; 2013 Oct; 198(1):271-4. PubMed ID: 23820134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
    Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
    J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
    Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
    Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec).
    Samoszuk M; Corwin MA
    Int J Cancer; 2003 Sep; 106(5):647-52. PubMed ID: 12866022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
    Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib responsiveness in canine mast cell tumors carrying novel mutations of c-KIT exon 11.
    Nakano Y; Kobayashi T; Oshima F; Fukazawa E; Yamagami T; Shiraishi Y; Takanosu M
    J Vet Med Sci; 2014 Apr; 76(4):545-8. PubMed ID: 24292246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib for systemic mast-cell disease.
    Pardanani A; Elliott M; Reeder T; Li CY; Baxter EJ; Cross NC; Tefferi A
    Lancet; 2003 Aug; 362(9383):535-6. PubMed ID: 12932387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    Demetri GD; von Mehren M; Blanke CD; Van den Abbeele AD; Eisenberg B; Roberts PJ; Heinrich MC; Tuveson DA; Singer S; Janicek M; Fletcher JA; Silverman SG; Silberman SL; Capdeville R; Kiese B; Peng B; Dimitrijevic S; Druker BJ; Corless C; Fletcher CD; Joensuu H
    N Engl J Med; 2002 Aug; 347(7):472-80. PubMed ID: 12181401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
    Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement.
    Marconato L; Bettini G; Giacoboni C; Romanelli G; Cesari A; Zatelli A; Zini E
    J Vet Intern Med; 2008; 22(4):1001-7. PubMed ID: 18564225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a secondary mutation in the KIT kinase domain correlated with imatinib-resistance in a canine mast cell tumor.
    Nakano Y; Kobayashi M; Bonkobara M; Takanosu M
    Vet Immunol Immunopathol; 2017 Jun; 188():84-88. PubMed ID: 28615132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats.
    Lachowicz JL; Post GS; Brodsky E
    J Vet Intern Med; 2005; 19(6):860-4. PubMed ID: 16355681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.